Description
Epidermal Growth Factor Receptor (EGFR) has emerged as a promising molecular target for the treatment of Head and neck squamous cell carcinoma (HNSCC). Investigators working at the University of Pittsburgh and Carnegie Mellon University have developed a class of EGFR antisense agents (EGFRAS) which contain a peptide backbone, called guanidinium peptide nucleic acids (GPNA). These EGFRASGPNAs are believed to bind to the transcriptional start site of the EGFR gene to induce potent and sequence-specific antisense effects while having low toxicity and high specificity.
IP Status
https://patents.google.com/patent/US9334496B2
